ArticleCancer immunology, immunotherapy : CII2006
Complement decay accelerating factor (DAF)/CD55 in cancer.
Article in Cancer immunology, immunotherapy : CII, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 66 citations in OpenAlex.
- Targeting endosomal trafficking-mediated antigen escape to resensitize myeloma to CAR-T therapy.Journal for immunotherapy of cancer · 2026Article
- A fully human IgG1 antibody targeting MICA α1 domain inhibits interaction with NKG2D and activates immune effector functions against MICA-expressing cells.Frontiers in immunology · 2026Article
- CD55 in cancer: Complementing functions in a non-canonical manner.Cancer letters · 2022Review
- Inhibition of complement activation by CD55 overexpression in human induced pluripotent stem cell derived kidney organoids.Frontiers in immunology · 2022Article
- Functional genetic variants in complement component 7 confer susceptibility to gastric cancer.PeerJ · 2022Article
- Complement System: An Immunotherapy Target in Colorectal Cancer.Frontiers in immunology · 2022Review
- GPI-AP: Unraveling a New Class of Malignancy Mediators and Potential Immunotherapy Targets.Frontiers in oncology · 2020Review
- Development of a radionuclide-labeled monoclonal anti-CD55 antibody with theranostic potential in pleural metastatic lung cancer.Scientific reports · 2018Article
- Network-based analysis of the molecular mechanisms of multiple myeloma and monoclonal gammopathy of undetermined significance.Oncology letters · 2017Article
- A common CD55 rs2564978 variant is associated with the susceptibility of non-small cell lung cancer.Oncotarget · 2017Article
- The dual role of complement in cancer and its implication in anti-tumor therapy.Annals of translational medicine · 2016Review
- Pathogenesis of human diffusely adhering Escherichia coli expressing Afa/Dr adhesins (Afa/Dr DAEC): current insights and future challenges.Clinical microbiology reviews · 2014Review
- Dysregulation of the complement cascade in the hSOD1G93A transgenic mouse model of amyotrophic lateral sclerosis.Journal of neuroinflammation · 2013Article
- Early onset and enhanced growth of autochthonous mammary carcinomas in C3-deficient Her2/neu transgenic mice.Oncoimmunology · 2013Article
- Opposing roles for complement component C5a in tumor progression and the tumor microenvironment.Journal of immunology (Baltimore, Md. : 1950) · 2012Article
- The invasion and metastasis promotion role of CD97 small isoform in gastric carcinoma.PloS one · 2012Article
- Dense deposit disease.Molecular immunology · 2011Review
- Decay accelerating factor (CD55)-mediated attenuation of complement: therapeutic implications for age-related macular degeneration.Investigative ophthalmology & visual science · 2010Article
- The impact of expressions of CD97 and its ligand CD55 at the invasion front on prognosis of rectal adenocarcinoma.International journal of colorectal disease · 2010Article
- Cancer and pregnancy: parallels in growth, invasion, and immune modulation and implications for cancer therapeutic agents.Mayo Clinic proceedings · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The complement system is a powerful innate mechanism involved in protection of the host against pathogens. It also has a role in the clearance of apoptotic cells and has been implicated in a range of pathologies including autoimmunity and graft rejection. The control of complement is mediated through the complement regulatory proteins (CRPs). These are present on most cells and protect normal cells from complement-mediated attack during innate activation. However, in a range of pathologies and cancer, these molecules are up or down regulated, sometimes secreted and even lost. We will review the expression of CRPs in cancer, focussing on CD55 and highlight other roles of the CRPs and their involvement in leukocyte function. We will also provide some data providing a potential mechanism by which soluble CD55 can inhibit T-cell function and discuss some of the implications of this data.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.